113 0 Kommentare Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform

FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.

“We expect to initiate the Phase 2 program for volasertib in patients with relapsed/refractory acute myeloid leukemia (r/r AML) utilizing our PPMP in Q2 2024. As we advance preparations for the study, we are pleased to share more data with the oncology community at AACR 2024 regarding our PPMP platform, including preclinical studies related to volasertib and innovation related to clinical response prediction from cryopreserved patient samples,” said Thomas Bock, M.D., Chief Executive Officer of Notable Labs.

Poster Details:

Poster #1: Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients

Session Category:	Clinical Research Excluding Trials
Session Title:	Predictive Biomarkers 4
Session Date and Time:	Tuesday Apr 9, 2024 9:00 AM - 12:30 PM PT
Location:	Poster Section 45
Poster Board Number:	19
Published Abstract Number:	5178

Poster #2: Retrospective prediction of clinical response to standard-of-care therapies in acute myeloid leukemia by an ex vivo drug sensitivity assay using cryopreserved primary samples

Session Category:	Clinical Research
Session Title:	Real-World Biomarkers
Session Date and Time:	Monday Apr 8, 2024 9:00 AM - 12:30 PM PT
Location:	Poster Section 45
Poster Board Number:	8
Published Abstract Number:	2548